Differentiation of SARS-CoV-2 naturally infected and vaccinated individuals in an inner-city emergency department

Background: Emergency Departments (EDs) can serve as surveillance sites for infectious diseases. Our purpose was to determine the burden of SARS-CoV-2 infection and prevalence of vaccination against COVID-19 among patients attending an urban ED in Baltimore City. Methods: Using 1914 samples of known exposure status, we developed an algorithm to differentiate previously infected, vaccinated, and unexposed individuals using a combination of antibody assays. We applied this testing algorithm to 4360 samples ED patients obtained in the springs of 2020 and 2021. Using multinomial logistic regression, we determined factors associated with infection and vaccination. Results: For the algorithm, sensitivity and specificity for identifying vaccinated individuals was 100% and 99%, respectively, and 84% and 100% for naturally infected individuals. Among the ED subjects, seroprevalence to SARS-CoV-2 increased from 2% to 24% between April 2020 and March 2021. Vaccination prevalence rose to 11% by mid-March 2021. Marked differences in burden of disease and vaccination coverage were seen by sex, race, and ethnicity. Hispanic patients, though 7% of the study population, had the highest relative burden of disease (17% of total infections) but similar vaccination rates. Women and White individuals were more likely to be vaccinated than men or Black individuals (adjusted odds ratios [aOR] 1.35 [95% CI: 1.02, 1.80] and aOR 2.26 [95% CI: 1.67, 3.07], respectively). Conclusions: Individuals previously infected with SARS-CoV-2 can be differentiated from vaccinated individuals using a serologic testing algorithm. SARS-CoV-2 exposure and vaccination uptake frequencies reflect gender, race and ethnic health disparities in this urban context.


Introduction
7 dataset. Data regarding COVID-19 vaccination status was not available. Laboratory testing was 151 then performed on stored specimens after delinking the demographic dataset. Using the unique 152 study code, SARS-CoV-2 serostatus and demographic data were then merged. 153 Laboratory Methods: 154 The testing algorithm required three serologic assays that could differentiate serologic reactivity 155 to SARS-CoV-2 S1, RBD and nucleocapsid. These assays were limited to standard ELISA and 156 point of care assays, as we did not have access to chemiluminescent detection equipment. We to differentiate samples into three groups: naturally infected (who may or may not subsequently 175 be vaccinated); vaccinated (who were never infected); and unexposed ( Figure 1). All samples were first tested using the Euroimmun ELISA (S1). Next, all positive and indeterminate samples 177 were subsequently tested on CoronaCHEK (RBD). Samples that tested positive on Euroimmun 178 and negative on CoronaCHEK were assumed to be false positives and classified as not naturally 179 infected or vaccinated (unexposed). Samples that tested positive on CoronaCHEK were then 180 tested with the Bio-Rad Total Ab assay (N). Samples which were reactive by Euroimmun and 181 CoronaCHEK but negative for Bio-Rad were considered vaccinated. Those samples with a 182 positive or indeterminate result on Bio-Rad were considered natural infections.

183
Statistical methods: 184 To evaluate the diagnostic accuracy of the testing algorithm for a particular state (vaccinated or 185 naturally infected), the sensitivity for each state was determined from samples with that known 186 status (the training sample sets; Table 1 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 using a t-test. Chi-squared and Fisher's exact tests was used to examine the differences in

219
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 There were significant differences between SARS-CoV-2 serostatus and the level of 220 antibody reactivity to spike and nucleocapsid among the cohorts used for algorithm validation 221 (Figure 2). For vaccinated individuals, the median S/C value for antibody reactivity against 222 spike was 8.9 (IQR=1.2) compared to 5.2 (IQR=5.3) for infected persons (p<0.001). Among the 223 vaccinated persons without previous infection, no individuals had an S/C value for antibody 224 reactivity against nucleocapsid greater than 0.8, the threshold for a positive result, whereas 225 naturally infected patients with no history of vaccination had a median S/C of 4.3 (IQR=0.53) 226 (p<0.001). Among HCP, there were 28 samples from individuals with a known SARS-CoV-2 227 PCR positive date who were vaccinated 7 to 103 days later. These individuals had spike antibody 228 S/C values similar to vaccinated individuals (median=9.5, IQR=0.9) and nucleocapsid antibody 229 S/C values similar to naturally infected individuals (median=3.4, IQR=2.9). Additionally, 18 230 HCP who were SARS-CoV-2 PCR negative but had suspected infection, had similar values to 231 those with known infection followed by vaccination, with spike antibody levels (median=10.0, 232 IQR=1.2) and nucleocapsid antibody S/C values (median=3.3 IQR 1.9). Because of the timing 233 of sample collection relative to vaccination, it is very unlikely that these 18 samples represented 234 breakthrough infections. It is more likely that these infections were unconfirmed infections that 235 occurred prior to vaccination. There was little reactivity for samples from pre-pandemic samples. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021.
periods were similar ( Table 2). For both surveys, approximately 27% were ≥60 years of age, 243 52% female, 60% Black, 26% White and 7% Hispanic. The prevalence of infection in the spring 244 of 2020 did not vary significantly by age, ethnicity, race and sex. In contrast, by the spring of 245 2021, significant differences in infection by age ethnicity, race and sex were observed.

246
The prevalence of antibodies to SARS-CoV-2 indicating previous infection or 247 vaccination is presented in Table 2. White women and men had the lowest prevalence of  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.13.21264968 doi: medRxiv preprint surveillance. Our study also confirms previous reports of high burden of COVID-19 among the 289 Baltimore Hispanic population 30 . Additionally, the discrepancies in vaccine uptake among racial 290 and ethnic minority groups are clearly demonstrated. While recent data suggest that racial and 291 ethnic gaps in vaccination have narrowed 10 , our data from early 2021 suggests that disparities in 292 vaccination were present in the initial stages of the vaccine rollout. Surprisingly, despite 293 prioritizing older Americans during the vaccine rollout 31 , patients older than 60 were as likely to 294 be vaccinated as those between the ages of 18-44.

295
Our method demonstrated 100% sensitivity in identifying individuals who were fully  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.    This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.13.21264968 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 Supplemental This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

584
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted October 14, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.